These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38114242)

  • 1. Factors associated with the response to postnatal dexamethasone use in very low birthweight infants: a nationwide cohort study.
    Baek SH; Shin JE; Han J; Song IG; Park J; Lee SM; Shim S; Eun HS; Lee SM; Lim J; Yoon SJ; Chang W; Park MS
    BMJ Paediatr Open; 2023 Dec; 7(1):. PubMed ID: 38114242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
    Doyle LW; Cheong JL; Ehrenkranz RA; Halliday HL
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001146. PubMed ID: 29063585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of risk factors for bronchopulmonary dysplasia with pulmonary hypertension and construction of a prediction nomogram model].
    Dai SZ; Li SS; Zhou MY; Xu Y; Zhang L; Zhang YH; Ye DN; Xu LP; Han SP
    Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):902-909. PubMed ID: 37803857
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants.
    Shah SS; Ohlsson A; Halliday HL; Shah VS
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD002057. PubMed ID: 29035425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk factors and prognosis of bronchopulmonary dysplasia associated pulmonary hypertension in preterm infants].
    Chen C; Huang P; Lin BC; Chen XY; Zhao J; Sun HY; Yu YL; Chen S; Qiu XM; Yang CZ
    Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):747-752. PubMed ID: 32872715
    [No Abstract]   [Full Text] [Related]  

  • 6. [Influencing factors for the development and severity of bronchopulmonary dysplasia in preterm infants with a gestational age of <32 weeks and a birth weight of <1 500 g].
    Huang J; Lin XZ; Zheng Z; Wang L; Ou FF
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Dec; 24(12):1326-1333. PubMed ID: 36544414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates.
    Shah SS; Ohlsson A; Halliday HL; Shah VS
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD002058. PubMed ID: 29041034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment.
    Yoo H; Lee JA; Oh S; Jung YH; Sohn JA; Shin SH; Choi CW; Kim EK; Kim HS; Kim BI
    J Korean Med Sci; 2017 Jan; 32(1):115-123. PubMed ID: 27914140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for moderate/severe bronchopulmonary dysplasia in preterm infants with a gestational age of <32 weeks: a multicenter retrospective analysis].
    Jiangsu Province Neonatal Perinatal Cooperation Network
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Oct; 24(10):1104-1110. PubMed ID: 36305110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and risk factors of very low birth weight and extremely low birth weight infants with bronchopulmonary dysplasia: multicenter retrospective analysis].
    Jiangsu Multicenter Study Collaborative Group for Breastmilk Feeding in Neonatal Intensive Care Units
    Zhonghua Er Ke Za Zhi; 2019 Jan; 57(1):33-39. PubMed ID: 30630229
    [No Abstract]   [Full Text] [Related]  

  • 11. Bronchopulmonary dysplasia in very and extremely low birth weight infants - analysis of selected risk factors.
    Kiciński P; Kęsiak M; Nowiczewski M; Gulczyńska E
    Pol Merkur Lekarski; 2017 Feb; 42(248):71-75. PubMed ID: 28258680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of patent ductus arteriosus shunt size and duration on risk of death or severe respiratory morbidity in preterm infants born in China.
    Deng Y; Zhang H; Zhao Z; Du J; Bai R; McNamara PJ
    Eur J Pediatr; 2022 Aug; 181(8):3131-3140. PubMed ID: 35838780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
    Doyle LW; Cheong JL; Hay S; Manley BJ; Halliday HL
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD001145. PubMed ID: 34758507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of bronchopulmonary dysplasia in very preterm infants.
    Yang Y; He X; Zhang X; Chen P
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 48(10):1592-1601. PubMed ID: 38432888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension.
    Gentle SJ; Travers CP; Clark M; Carlo WA; Ambalavanan N
    Am J Respir Crit Care Med; 2023 Apr; 207(7):921-928. PubMed ID: 36378949
    [No Abstract]   [Full Text] [Related]  

  • 16. [Establishment and efficiency test of a clinical prediction model of bronchopulmonary dysplasia associated pulmonary hypertension in very premature infants].
    Cao JK; Fan HQ; Xiao YB; Wang D; Liu CG; Peng XM; Gao XR; Tang SH; Han T; Mei YB; Liang HY; Wang SM; Wang F; Li QP
    Zhonghua Er Ke Za Zhi; 2024 Feb; 62(2):129-137. PubMed ID: 38264812
    [No Abstract]   [Full Text] [Related]  

  • 17. Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
    Doyle LW; Cheong JL; Hay S; Manley BJ; Halliday HL
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD001146. PubMed ID: 34674229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.
    Slaughter JL; Reagan PB; Newman TB; Klebanoff MA
    JAMA Pediatr; 2017 Mar; 171(3):e164354. PubMed ID: 28046188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.
    Onland W; De Jaegere AP; Offringa M; van Kaam A
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010941. PubMed ID: 28141913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting length of stay according to bronchopulmonary dysplasia severity: a nationwide cohort study in Korea.
    Lee HM; Shin J; Kim SY; Kim SY
    World J Pediatr; 2024 May; 20(5):470-480. PubMed ID: 38356035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.